Overview

* Genelux ( GNLX ) Q3 net loss of $7.95 mln beats analyst expectations

* Company has $21 mln in cash and investments, funding operations into Q3 2026

Outlook

* Company expects cash resources to support operations into Q3 2026

Result Drivers

* R&D EXPENSES - Increase in R&D expenses driven by stock compensation and clinical trial costs for Phase 3 OnPrime trial

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$7.95 -$8.14

Income mln mln (4

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Genelux Corp ( GNLX ) is $18.00, about 54.9% above its November 4 closing price of $8.11

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)